Common name: recombinant human nerve growth factor eye drops

Research Progress: obtain clinical approval

Potential indications: neurotrophic keratitis, moderate to severe dry eye, optic nerve injury, ischemic stroke

Description:

1. Drugs are urgently needed in clinic to replace imported varieties; The first manufacturer in China to declare the indications of neurotrophic keratitis.

2. Direct repair of damaged corneal nerve cells can completely cure the disease. Preclinical animal trials have shown that it can improve tear indicators, so it can be used in the treatment of dry eye. Relying on the development of the company's inclusion body renaturation technology platform, we have overcome the technical problems of inclusion body renaturation, reached the international advanced technology level of the same kind, owned independent intellectual property rights, and applied for invention patents for relevant innovative technologies.